CAMBRIDGE, Mass. , Aug. 14, 2017 /PRNewswire/ -- Merrimack Pharmaceuticals (NASDAQ: MACK) today announced that it has strengthened its executive management team with the appointment of Jean M. Franchi as Chief Financial Officer, effective August 21, 2017 . In this role, Ms.
- Announced hiring of industry veterans Dr. Sergio Santillana as Chief Medical Officer and Thomas Needham as Chief Business Officer to bolster executive team -<br>- Phase 2 CARRIE study of MM-141 completed enrollment with data expected in first half of 2018 -<br>- Conference call at 8:30 am ET today -
CAMBRIDGE, Mass. , Aug. 2, 2017 /PRNewswire/ -- Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) today announced that the company will host its second quarter 2017 investor conference call and webcast at 8:30 am ET on Wednesday, August 9, 2017. The call will cover an update on Merrimack's recent
CAMBRIDGE, Mass. , June 19, 2017 /PRNewswire/ -- Merrimack Pharmaceuticals, Inc. (NASDAQ: MACK) today announced that it has enrolled the last patient in the ongoing CARRIE study, a Phase 2, double-blind, placebo-controlled, randomized trial, evaluating MM-141 (istiratumab) in combination with
CAMBRIDGE, Mass. , May 25, 2017 /PRNewswire/ -- Merrimack Pharmaceuticals, Inc. (NASDAQ: MACK) today announced the resignation of Dr. Yasir Al-Wakeel as Chief Financial Officer and Head of Corporate Development, effective June 9, 2017 . Dr. Al-Wakeel , who has been in his role with Merrimack since
Completes asset sale to Ipsen for up to $1.025 billion in cash and potential milestones payments; declares special cash dividend to stockholders of $140 million<br>Initiates Phase 1 clinical study of antibody-directed nanotherapeutic (ADN) MM-310; data expected in 2018<br>Conference call at 8:30 am ET today
CAMBRIDGE, Mass. , May 2, 2017 /PRNewswire/ -- Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) today announced that the company will host its first quarter 2017 investor conference call and webcast at 8:30 am ET on Wednesday, May 10, 2017. The call will cover an update on Merrimack's recent
CAMBRIDGE, Mass. , April 17, 2017 /PRNewswire/ -- Merrimack Pharmaceuticals, Inc. (NASDAQ: MACK) today announced that Daryl Drummond , Ph.D. has been appointed Head of Research. Dr. Drummond , an expert and pioneer in the field of nanotherapeutics, has held various leadership roles at Merrimack,